Toll Free: 1-888-928-9744

Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 92 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Pipeline Review, H1 2016', provides in depth analysis on Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted pipeline therapeutics. 

The report provides comprehensive information on the Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22)
- The report reviews Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 7 Global Markets Direct Report Coverage 7 Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Overview 8 Therapeutics Development 9 Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Products under Development by Stage of Development 9 Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Products under Development by Therapy Area 10 Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Products under Development by Indication 11 Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Pipeline Products Glance 13 Late Stage Products 13 Early Stage Products 14 Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Products under Development by Companies 15 Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Products under Development by Universities/Institutes 20 Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Therapeutics Assessment 22 Assessment by Monotherapy/Combination Products 22 Assessment by Mechanism of Action 23 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Companies Involved in Therapeutics Development 28 Beta Pharma, Inc. 28 Eli Lilly and Company 29 G1 Therapeutics, Inc. 30 Jiangsu Hengrui Medicine Co., Ltd. 31 Novartis AG 32 Onconova Therapeutics, Inc. 33 Pfizer Inc. 34 Sihuan Pharmaceutical Holdings Group Ltd. 35 Teijin Pharma Limited 36 ViroStatics srl 37 Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Drug Profiles 38 abemaciclib - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 BPI-1178 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 FLX-925 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 G-1T28 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 G-1T38 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 GZ-381 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 MMD-37K - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 ON-123300 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 palbociclib - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 ribociclib succinate - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 SHR-6390 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 Small Molecule to Inhibit CDK4 and CDK6 for Breast Cancer - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HSV Infections - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 Small Molecule to Inhibit CDK4, CDK6 and CDK9 for Oncology - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 Small Molecules to Inhibit Cyclin D1, CDK6, EGFR and VEGF for Oncology - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Dormant Projects 74 Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Discontinued Products 75 Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) - Featured News & Press Releases 76 Jun 03, 2016: Lilly Announces Results From MONARCH 1 Trial Of Abemaciclib Monotherapy 76 May 31, 2016: Lilly Announces Webcast To Discuss Abemaciclib Data 77 May 23, 2016: Investigational CDK4/6 inhibitor abemaciclib is active against a range of cancer types 77 May 18, 2016: Eli Lilly to Present final phase 2 monotherapy data on CDK 4 and 6 inhibitor abemaciclib in metastatic breast cancer at ASCO 78 May 18, 2016: MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer 79 May 10, 2016: Health Canada approves new first-line treatment for women living with metastatic breast cancer 80 Apr 20, 2016: Onconova Announces Novel Dual Targeting of ARK5 and CDK4/6 by Pre-clinical Compound, ON 123300, in Presentation at 2016 American Association of Cancer Research (AACR) Annual Meeting 81 Apr 19, 2016: Pfizer Announces Positive Top-Line Results For Phase 3 PALOMA-2 Clinical Trial Of IBRANCE (Palbociclib) 82 Apr 15, 2016: G1 Therapeutics to Present Preliminary clinical data on CDK4/6 Inhibitor G1T28 at the 2016 American Association for Cancer Research Annual Meeting 83 Apr 15, 2016: G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitor G1T38 at the 2016 American Association for Cancer Research Annual Meeting 84 Mar 14, 2016: New agent overcomes drug resistance in HER2-positive breast cancer preclinical study shows 84 Mar 07, 2016: New therapeutic target in myeloma discovered 86 Mar 02, 2016: Drug combination slows breast cancer spread 87 Feb 19, 2016: Pfizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer 88 Dec 29, 2015: New breast cancer drug may be effective against other types of cancer 90 Appendix 91 Methodology 91 Coverage 91 Secondary Research 91 Primary Research 91 Expert Panel Validation 91 Contact Us 91 Disclaimer 92
List of Tables
Number of Products under Development for, H1 2016 9 Number of Products under Development by Therapy Area, H1 2016 10 Number of Products under Development by Indication, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Early Stage Products, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Development by Companies, H1 2016 (Contd..1) 17 Products under Development by Companies, H1 2016 (Contd..2) 18 Products under Development by Companies, H1 2016 (Contd..3) 19 Number of Products under Investigation by Universities/Institutes, H1 2016 20 Products under Investigation by Universities/Institutes, H1 2016 21 Assessment by Monotherapy/Combination Products, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Pipeline by Beta Pharma, Inc., H1 2016 28 Pipeline by Eli Lilly and Company, H1 2016 29 Pipeline by G1 Therapeutics, Inc., H1 2016 30 Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016 31 Pipeline by Novartis AG, H1 2016 32 Pipeline by Onconova Therapeutics, Inc., H1 2016 33 Pipeline by Pfizer Inc., H1 2016 34 Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016 35 Pipeline by Teijin Pharma Limited, H1 2016 36 Pipeline by ViroStatics srl, H1 2016 37 Dormant Projects, H1 2016 74 Discontinued Products, H1 2016 75



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $3500
Multi User - US $7000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify